Skip to main content
Top
Published in: Molecular Cancer 1/2012

Open Access 01-12-2012 | Research

Targeting of MAPK-associated molecules identifies SON as a prime target to attenuate the proliferation and tumorigenicity of pancreatic cancer cells

Authors: Toru Furukawa, Etsuko Tanji, Yuko Kuboki, Takashi Hatori, Masakazu Yamamoto, Kyoko Shimizu, Noriyuki Shibata, Keiko Shiratori

Published in: Molecular Cancer | Issue 1/2012

Login to get access

Abstract

Background

Pancreatic cancer is characterized by constitutive activation of mitogen-activated protein kinase (MAPK). Activation of MAPK is associated with the upregulation of genes implicated in the proliferation and survival of pancreatic cancer cells. We hypothesized that knockdown of these MAPK-associated molecules could produce notable anticancer phenotypes.

Methods

A RNA interference-mediated knockdown screening of 78 MAPK-associated molecules previously identified was performed to find molecules specifically associated with proliferation of pancreatic cancer cells in vitro. Expression of an identified molecule in pancreatic cancer tissues was examined by immunohistochemistry. In vivo tumorigenicity of cancer cells with stable knockdown of the molecule was assayed by using xenograft models. Flow cytometry and live cell imaging were employed to assess an association of the molecule with cell cycle.

Results

The knockdown screening revealed that knockdown of SON, the gene encoding SON, which is a large serine/arginine-rich protein involved in RNA processing, substantially suppressed pancreatic cancer cell proliferation and survival in vitro and tumorigenicity in vivo. SON expression was higher in ductal adenocarcinomas than in cells of normal ducts and precursor lesions in pancreatic cancer tissues. Knockdown of SON induced G2/M arrest and apoptosis in cultured cancer cells. The suppressive effect of SON knockdown on proliferation was less pronounced in cultured normal duct epithelial cells. SON formed nuclear speckles in the interphase of the cell cycle and dispersed in the cytoplasm during mitosis. Live cell imaging showed that SON diffusely dispersed in the early mitotic phase, accumulated in some foci in the cytoplasm in the late mitotic phase, and gradually reassembled into speckles after mitosis.

Conclusion

These results indicate that SON plays a critical role in the proliferation, survival, and tumorigenicity of pancreatic cancer cells, suggesting that SON is a novel therapeutic molecular target for pancreatic cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cancer statistics in Japan. Edited by: Kato H, Sobue T, Katanoda K, Saito Y, Tsukuma H, Sakura N, Kitai A. 2008, National Cancer Center, Tokyo. Cancer statistics in Japan. Edited by: Kato H, Sobue T, Katanoda K, Saito Y, Tsukuma H, Sakura N, Kitai A. 2008, National Cancer Center, Tokyo.
2.
go back to reference Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59 (4): 225-249. 10.3322/caac.20006CrossRefPubMed Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59 (4): 225-249. 10.3322/caac.20006CrossRefPubMed
3.
go back to reference Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, Santaquilani M: Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol. 2007, 8 (9): 773-783. 10.1016/S1470-2045(07)70245-0CrossRefPubMed Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, Santaquilani M: Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol. 2007, 8 (9): 773-783. 10.1016/S1470-2045(07)70245-0CrossRefPubMed
4.
go back to reference O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003, 348 (11): 994-1004. 10.1056/NEJMoa022457CrossRefPubMed O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003, 348 (11): 994-1004. 10.1056/NEJMoa022457CrossRefPubMed
5.
go back to reference Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988, 53 (4): 549-554.CrossRefPubMed Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988, 53 (4): 549-554.CrossRefPubMed
6.
go back to reference Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, Hempen PM, Hilgers W, Yeo CJ, Hruban RH: BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol. 2003, 163 (4): 1255-1260. 10.1016/S0002-9440(10)63485-2PubMedCentralCrossRefPubMed Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, Hempen PM, Hilgers W, Yeo CJ, Hruban RH: BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol. 2003, 163 (4): 1255-1260. 10.1016/S0002-9440(10)63485-2PubMedCentralCrossRefPubMed
7.
go back to reference Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A: Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol. 2003, 162 (6): 1807-1815. 10.1016/S0002-9440(10)64315-5PubMedCentralCrossRefPubMed Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A: Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol. 2003, 162 (6): 1807-1815. 10.1016/S0002-9440(10)64315-5PubMedCentralCrossRefPubMed
8.
go back to reference Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouyssegur J: Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J. 1999, 18 (3): 664-674. 10.1093/emboj/18.3.664PubMedCentralCrossRefPubMed Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouyssegur J: Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J. 1999, 18 (3): 664-674. 10.1093/emboj/18.3.664PubMedCentralCrossRefPubMed
9.
go back to reference Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A, Horii A: AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene. 2006, 25 (35): 4831-4839. 10.1038/sj.onc.1209494CrossRefPubMed Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A, Horii A: AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene. 2006, 25 (35): 4831-4839. 10.1038/sj.onc.1209494CrossRefPubMed
10.
go back to reference Hata T, Furukawa T, Sunamura M, Egawa S, Motoi F, Ohmura N, Marumoto T, Saya H, Horii A: RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. 2005, 65 (7): 2899-2905. 10.1158/0008-5472.CAN-04-3981CrossRefPubMed Hata T, Furukawa T, Sunamura M, Egawa S, Motoi F, Ohmura N, Marumoto T, Saya H, Horii A: RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. 2005, 65 (7): 2899-2905. 10.1158/0008-5472.CAN-04-3981CrossRefPubMed
11.
go back to reference Sun C, Yamato T, Furukawa T, Ohnishi Y, Kijima H, Horii A: Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol Rep. 2001, 8 (1): 89-92.PubMed Sun C, Yamato T, Furukawa T, Ohnishi Y, Kijima H, Horii A: Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol Rep. 2001, 8 (1): 89-92.PubMed
12.
go back to reference Furukawa T, Duguid WP, Rosenberg L, Viallet J, Galloway DA, Tsao MS: Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol. 1996, 148 (6): 1763-1770.PubMedCentralPubMed Furukawa T, Duguid WP, Rosenberg L, Viallet J, Galloway DA, Tsao MS: Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol. 1996, 148 (6): 1763-1770.PubMedCentralPubMed
13.
go back to reference Yamanaka S, Sunamura M, Furukawa T, Sun L, Lefter LP, Abe T, Yatsuoka T, Fujimura H, Shibuya E, Kotobuki N: Chromosome 12, frequently deleted in human pancreatic cancer, may encode a tumor-suppressor gene that suppresses angiogenesis. Lab Invest. 2004, 84 (10): 1339-1351. 10.1038/labinvest.3700160CrossRefPubMed Yamanaka S, Sunamura M, Furukawa T, Sun L, Lefter LP, Abe T, Yatsuoka T, Fujimura H, Shibuya E, Kotobuki N: Chromosome 12, frequently deleted in human pancreatic cancer, may encode a tumor-suppressor gene that suppresses angiogenesis. Lab Invest. 2004, 84 (10): 1339-1351. 10.1038/labinvest.3700160CrossRefPubMed
14.
go back to reference Lens SM, Voest EE, Medema RH: Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer. 2010, 10 (12): 825-841. 10.1038/nrc2964CrossRefPubMed Lens SM, Voest EE, Medema RH: Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer. 2010, 10 (12): 825-841. 10.1038/nrc2964CrossRefPubMed
15.
go back to reference Verdaasdonk JS, Bloom K: Centromeres: unique chromatin structures that drive chromosome segregation. Nat Rev Mol Cell Biol. 2011, 12 (5): 320-332. 10.1038/nrm3107PubMedCentralCrossRefPubMed Verdaasdonk JS, Bloom K: Centromeres: unique chromatin structures that drive chromosome segregation. Nat Rev Mol Cell Biol. 2011, 12 (5): 320-332. 10.1038/nrm3107PubMedCentralCrossRefPubMed
16.
go back to reference Hirano Y, Ishii K, Kumeta M, Furukawa K, Takeyasu K, Horigome T: Proteomic and targeted analytical identification of BXDC1 and EBNA1BP2 as dynamic scaffold proteins in the nucleolus. Genes Cells. 2009, 14 (2): 155-166. 10.1111/j.1365-2443.2008.01262.xCrossRefPubMed Hirano Y, Ishii K, Kumeta M, Furukawa K, Takeyasu K, Horigome T: Proteomic and targeted analytical identification of BXDC1 and EBNA1BP2 as dynamic scaffold proteins in the nucleolus. Genes Cells. 2009, 14 (2): 155-166. 10.1111/j.1365-2443.2008.01262.xCrossRefPubMed
17.
go back to reference Conchon S, Cao X, Barlowe C, Pelham HR: Got1p and Sft2p: membrane proteins involved in traffic to the Golgi complex. EMBO J. 1999, 18 (14): 3934-3946. 10.1093/emboj/18.14.3934PubMedCentralCrossRefPubMed Conchon S, Cao X, Barlowe C, Pelham HR: Got1p and Sft2p: membrane proteins involved in traffic to the Golgi complex. EMBO J. 1999, 18 (14): 3934-3946. 10.1093/emboj/18.14.3934PubMedCentralCrossRefPubMed
18.
go back to reference Valentine MT, Gilbert SP: To step or not to step? How biochemistry and mechanics influence processivity in Kinesin and Eg5. Curr Opin Cell Biol. 2007, 19 (1): 75-81. 10.1016/j.ceb.2006.12.011PubMedCentralCrossRefPubMed Valentine MT, Gilbert SP: To step or not to step? How biochemistry and mechanics influence processivity in Kinesin and Eg5. Curr Opin Cell Biol. 2007, 19 (1): 75-81. 10.1016/j.ceb.2006.12.011PubMedCentralCrossRefPubMed
19.
go back to reference Gao S, Alarcon C, Sapkota G, Rahman S, Chen PY, Goerner N, Macias MJ, Erdjument-Bromage H, Tempst P, Massague J: Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling. Mol Cell. 2009, 36 (3): 457-468. 10.1016/j.molcel.2009.09.043PubMedCentralCrossRefPubMed Gao S, Alarcon C, Sapkota G, Rahman S, Chen PY, Goerner N, Macias MJ, Erdjument-Bromage H, Tempst P, Massague J: Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling. Mol Cell. 2009, 36 (3): 457-468. 10.1016/j.molcel.2009.09.043PubMedCentralCrossRefPubMed
20.
go back to reference Giubettini M, Asteriti IA, Scrofani J, De Luca M, Lindon C, Lavia P, Guarguaglini G: Control of Aurora-A stability through interaction with TPX2. J Cell Sci. 2011, 124 (Pt 1): 113-122.PubMedCentralCrossRefPubMed Giubettini M, Asteriti IA, Scrofani J, De Luca M, Lindon C, Lavia P, Guarguaglini G: Control of Aurora-A stability through interaction with TPX2. J Cell Sci. 2011, 124 (Pt 1): 113-122.PubMedCentralCrossRefPubMed
21.
go back to reference Wysocka J, Swigut T, Milne TA, Dou Y, Zhang X, Burlingame AL, Roeder RG, Brivanlou AH, Allis CD: WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. Cell. 2005, 121 (6): 859-872. 10.1016/j.cell.2005.03.036CrossRefPubMed Wysocka J, Swigut T, Milne TA, Dou Y, Zhang X, Burlingame AL, Roeder RG, Brivanlou AH, Allis CD: WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. Cell. 2005, 121 (6): 859-872. 10.1016/j.cell.2005.03.036CrossRefPubMed
22.
go back to reference Addepalli MK, Ray KB, Kumar B, Ramnath RL, Chile S, Rao H: RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression. Gene Ther. 2010, 17 (3): 352-359. 10.1038/gt.2009.155CrossRefPubMed Addepalli MK, Ray KB, Kumar B, Ramnath RL, Chile S, Rao H: RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression. Gene Ther. 2010, 17 (3): 352-359. 10.1038/gt.2009.155CrossRefPubMed
23.
go back to reference Li Y, Zhu Z, Zhang S, Yu D, Yu H, Liu L, Cao X, Wang L, Gao H, Zhu M: ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth. PLoS One. 2011, 6 (3): e17794- 10.1371/journal.pone.0017794PubMedCentralCrossRefPubMed Li Y, Zhu Z, Zhang S, Yu D, Yu H, Liu L, Cao X, Wang L, Gao H, Zhu M: ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth. PLoS One. 2011, 6 (3): e17794- 10.1371/journal.pone.0017794PubMedCentralCrossRefPubMed
24.
go back to reference Liu M, Yu H, Huo L, Liu J, Li M, Zhou J: Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor. Biochem Pharmacol. 2008, 76 (2): 169-178. 10.1016/j.bcp.2008.04.018CrossRefPubMed Liu M, Yu H, Huo L, Liu J, Li M, Zhou J: Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor. Biochem Pharmacol. 2008, 76 (2): 169-178. 10.1016/j.bcp.2008.04.018CrossRefPubMed
25.
go back to reference Li B, Qi XQ, Chen X, Huang X, Liu GY, Chen HR, Huang CG, Luo C, Lu YC: Expression of targeting protein for Xenopus kinesin-like protein 2 is associated with progression of human malignant astrocytoma. Brain Res. 2010, 1352: 200-207.CrossRefPubMed Li B, Qi XQ, Chen X, Huang X, Liu GY, Chen HR, Huang CG, Luo C, Lu YC: Expression of targeting protein for Xenopus kinesin-like protein 2 is associated with progression of human malignant astrocytoma. Brain Res. 2010, 1352: 200-207.CrossRefPubMed
26.
go back to reference Mattioni T, Hume CR, Konigorski S, Hayes P, Osterweil Z, Lee JS: A cDNA clone for a novel nuclear protein with DNA binding activity. Chromosoma. 1992, 101 (10): 618-624. 10.1007/BF00360539CrossRefPubMed Mattioni T, Hume CR, Konigorski S, Hayes P, Osterweil Z, Lee JS: A cDNA clone for a novel nuclear protein with DNA binding activity. Chromosoma. 1992, 101 (10): 618-624. 10.1007/BF00360539CrossRefPubMed
27.
go back to reference Sun CT, Lo WY, Wang IH, Lo YH, Shiou SR, Lai CK, Ting LP: Transcription repression of human hepatitis B virus genes by negative regulatory element-binding protein/SON. J Biol Chem. 2001, 276 (26): 24059-24067. 10.1074/jbc.M101330200CrossRefPubMed Sun CT, Lo WY, Wang IH, Lo YH, Shiou SR, Lai CK, Ting LP: Transcription repression of human hepatitis B virus genes by negative regulatory element-binding protein/SON. J Biol Chem. 2001, 276 (26): 24059-24067. 10.1074/jbc.M101330200CrossRefPubMed
28.
go back to reference Ahn EY, Yan M, Malakhova OA, Lo MC, Boyapati A, Ommen HB, Hines R, Hokland P, Zhang DE: Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis. Proc Natl Acad Sci U S A. 2008, 105 (44): 17103-17108. 10.1073/pnas.0802696105PubMedCentralCrossRefPubMed Ahn EY, Yan M, Malakhova OA, Lo MC, Boyapati A, Ommen HB, Hines R, Hokland P, Zhang DE: Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis. Proc Natl Acad Sci U S A. 2008, 105 (44): 17103-17108. 10.1073/pnas.0802696105PubMedCentralCrossRefPubMed
29.
go back to reference Sharma A, Takata H, Shibahara K, Bubulya A, Bubulya PA: Son is essential for nuclear speckle organization and cell cycle progression. Mol Biol Cell. 2010, 21 (4): 650-663. 10.1091/mbc.E09-02-0126PubMedCentralCrossRefPubMed Sharma A, Takata H, Shibahara K, Bubulya A, Bubulya PA: Son is essential for nuclear speckle organization and cell cycle progression. Mol Biol Cell. 2010, 21 (4): 650-663. 10.1091/mbc.E09-02-0126PubMedCentralCrossRefPubMed
30.
go back to reference Ahn EY, DeKelver RC, Lo MC, Nguyen TA, Matsuura S, Boyapati A, Pandit S, Fu XD, Zhang DE: SON controls cell-cycle progression by coordinated regulation of RNA splicing. Mol Cell. 2011, 42 (2): 185-198. 10.1016/j.molcel.2011.03.014PubMedCentralCrossRefPubMed Ahn EY, DeKelver RC, Lo MC, Nguyen TA, Matsuura S, Boyapati A, Pandit S, Fu XD, Zhang DE: SON controls cell-cycle progression by coordinated regulation of RNA splicing. Mol Cell. 2011, 42 (2): 185-198. 10.1016/j.molcel.2011.03.014PubMedCentralCrossRefPubMed
31.
go back to reference Leser GP, Fakan S, Martin TE: Ultrastructural distribution of ribonucleoprotein complexes during mitosis. snRNP antigens are contained in mitotic granule clusters. Eur J Cell Biol. 1989, 50 (2): 376-389.PubMed Leser GP, Fakan S, Martin TE: Ultrastructural distribution of ribonucleoprotein complexes during mitosis. snRNP antigens are contained in mitotic granule clusters. Eur J Cell Biol. 1989, 50 (2): 376-389.PubMed
32.
go back to reference Prasanth KV, Sacco-Bubulya PA, Prasanth SG, Spector DL: Sequential entry of components of the gene expression machinery into daughter nuclei. Mol Biol Cell. 2003, 14 (3): 1043-1057. 10.1091/mbc.E02-10-0669PubMedCentralCrossRefPubMed Prasanth KV, Sacco-Bubulya PA, Prasanth SG, Spector DL: Sequential entry of components of the gene expression machinery into daughter nuclei. Mol Biol Cell. 2003, 14 (3): 1043-1057. 10.1091/mbc.E02-10-0669PubMedCentralCrossRefPubMed
33.
go back to reference Bubulya PA, Prasanth KV, Deerinck TJ, Gerlich D, Beaudouin J, Ellisman MH, Ellenberg J, Spector DL: Hypophosphorylated SR splicing factors transiently localize around active nucleolar organizing regions in telophase daughter nuclei. J Cell Biol. 2004, 167 (1): 51-63. 10.1083/jcb.200404120PubMedCentralCrossRefPubMed Bubulya PA, Prasanth KV, Deerinck TJ, Gerlich D, Beaudouin J, Ellisman MH, Ellenberg J, Spector DL: Hypophosphorylated SR splicing factors transiently localize around active nucleolar organizing regions in telophase daughter nuclei. J Cell Biol. 2004, 167 (1): 51-63. 10.1083/jcb.200404120PubMedCentralCrossRefPubMed
34.
go back to reference Lamond AI, Spector DL: Nuclear speckles: a model for nuclear organelles. Nat Rev Mol Cell Biol. 2003, 4 (8): 605-612. 10.1038/nrm1172CrossRefPubMed Lamond AI, Spector DL: Nuclear speckles: a model for nuclear organelles. Nat Rev Mol Cell Biol. 2003, 4 (8): 605-612. 10.1038/nrm1172CrossRefPubMed
35.
go back to reference Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A: Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010, 464 (7291): 1067-1070. 10.1038/nature08956PubMedCentralCrossRefPubMed Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A: Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010, 464 (7291): 1067-1070. 10.1038/nature08956PubMedCentralCrossRefPubMed
36.
go back to reference Kuboki Y, Shiratori K, Hatori T, Fujita I, Kimijima A, Yamamoto M, Kobayashi M, Furukawa T: Association of epidermal growth factor receptor and mitogen-activated protein kinase with cystic neoplasms of the pancreas. Mod Pathol. 2010, 23 (8): 1127-1135. 10.1038/modpathol.2010.97CrossRefPubMed Kuboki Y, Shiratori K, Hatori T, Fujita I, Kimijima A, Yamamoto M, Kobayashi M, Furukawa T: Association of epidermal growth factor receptor and mitogen-activated protein kinase with cystic neoplasms of the pancreas. Mod Pathol. 2010, 23 (8): 1127-1135. 10.1038/modpathol.2010.97CrossRefPubMed
Metadata
Title
Targeting of MAPK-associated molecules identifies SON as a prime target to attenuate the proliferation and tumorigenicity of pancreatic cancer cells
Authors
Toru Furukawa
Etsuko Tanji
Yuko Kuboki
Takashi Hatori
Masakazu Yamamoto
Kyoko Shimizu
Noriyuki Shibata
Keiko Shiratori
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2012
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-11-88

Other articles of this Issue 1/2012

Molecular Cancer 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine